Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination

Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination

Bibliographic Details
Main Authors:	Oliver, A, Bjermer, L, Quinn, D, Saggu, P, Thomas, P, Yarnall, K, Lötvall, J
Format:	Online
Language:	English
Published:	BlackWell Publishing Ltd 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223930/

Similar Items

Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
by: O’Byrne, Paul M., et al.
Published: (2014)

A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects
by: Kempsford, Rodger, et al.
Published: (2014)

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
by: Bateman, Eric D, et al.
Published: (2014)

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
by: Brealey, Noushin, et al.
Published: (2015)

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
Published: (2016)

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
by: Covelli, Henry, et al.
Published: (2015)

Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
by: Chen, Xia, et al.
Published: (2015)

Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma: A Randomized Trial
by: Woodcock, Ashley, et al.
Published: (2013)

Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial
by: Lötvall, J, et al.
Published: (2012)

Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD
by: Caramori, Gaetano, et al.
Published: (2014)

Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy
by: Svedsater, Henrik, et al.
Published: (2016)

Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial
by: Oliver, Amanda, et al.
Published: (2012)

Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS
by: Vallejo-Aparicio LA, et al.
Published: (2018-09-01)

Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial
by: George Bardsley, et al.
Published: (2018-07-01)

Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease
by: Siederer, Sarah, et al.
Published: (2015)

Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy
by: Albertson, Timothy E, et al.
Published: (2016)

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy
by: Stynes, Gillian, et al.
Published: (2015)

Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis
by: Aneeza, W. Hamizan, et al.
Published: (2013)

New combination treatments in the management of asthma: focus on fluticasone/vilanterol
by: Tan, Laren D, et al.
Published: (2014)

Fluticasone furoate/fluticasone propionate – different drugs with different properties
by: Biggadike, Keith
Published: (2011)

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
by: Busse, William W, et al.
Published: (2013)

Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials
by: Gross, Annette S., et al.
Published: (2015)

Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study
by: Allen, Ann, et al.
Published: (2013)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
by: Singh, Dave, et al.
Published: (2015)

Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial
by: Busse, W W, et al.
Published: (2014)

Suppression of Cytokine Release by Fluticasone Furoate vs. Mometasone Furoate in Human Nasal Tissue Ex-Vivo
by: Zhang, Nan, et al.
Published: (2014)

The Relationship Between Fluticasone Furoate Systemic Exposure and Cortisol Suppression
by: Allen, Ann
Published: (2013)

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma
by: O’Byrne, Paul M., et al.
Published: (2016)

Fluticasone Furoate, a Novel Inhaled Corticosteroid, Demonstrates Prolonged Lung Absorption Kinetics in Man Compared with Inhaled Fluticasone Propionate
by: Allen, Ann, et al.
Published: (2012)

Patient perspectives on fluticasone–vilanterol versus other corticosteroid combination products for the treatment of asthma
by: Bollmeier, Suzanne G, et al.
Published: (2016)

Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial
by: Woodcock, Ashley, et al.
Published: (2011)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
by: Woodcock, Ashley, et al.
Published: (2011)

Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial
by: O’Byrne, Paul M, et al.
Published: (2014)

Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice
by: Singam, Rajeswari, et al.
Published: (2006)

Non-inferiority efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma
by: Bernstein, David I, et al.
Published: (2010)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
by: Bernstein, David I, et al.
Published: (2011)

Allergens induce enhanced bronchoconstriction and leukotriene production in C5 deficient mice
by: McKinley, Laura, et al.
Published: (2006)

Comparing the effects of two inhaled glucocorticoids on allergen-induced bronchoconstriction and markers of systemic effects, a randomised cross-over double-blind study
by: Lötvall, Jan, et al.
Published: (2011)

Efficacy and safety of fluticasone furoate nasal spray in adult and adolescent subjects with uncomplicated acute rhinosinusitis
by: Keith, Paul, et al.
Published: (2011)

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol Alone and in Combination: A Randomized Crossover Trial
by: Kelleher, Dennis L., et al.
Published: (2012)